Our Mission

Fully dedicated to saving lives, curing life threatening diseases, and improving quality of life for millions of people suffering from skin disorders.

Who we are

BirchBioMed is an advanced clinical-stage biopharmaceutical company headquartered in Toronto (Canada). We are dedicated to the development of innovative and groundbreaking treatments of mild to severe medical disorders and devastating diseases with high unmet medical need, affecting the quality of life and life expectancy of million patients (pediatric and adult) in the World.

We hold exclusive, worldwide pharmaceutical licenses from the prestigious University of British Columbia (UBC) in Canada for two groundbreaking technologies: FS2 (kynurenic acid / KynA) and AI-001, a novel, proprietary combination of KynA with Antigen Presenting Cells (APC’s) therapy.

Our preliminary research and early-to-mid-stage clinical trials have demonstrated that FS2 and AI-001 have the potential to be revolutionary treatments for multiple life-threatening diseases and severe debilitating conditions.

Our Vision and Mission

Our mission is to develop FS2 as the first line treatment for millions suffering from organ fibrosis, such as Idiopathic Pulmonary Fibrosis —a condition currently fatal in nearly all cases within 2 to 5 or 7 years after being diagnosed. Additionally, we are developing AI-001, aimed at radically improving the lives of patients with specific autoimmune disorders, initially focusing on Type 1 Diabetes, which affect hundreds of thousands of patients worldwide every year from young to old, and Alopecia Areata.

Beyond its potential to significantly improve the quality of life and to possibly revert the progression of life-threatening diseases, FS2 has also demonstrated exceptional results as a topical cream in treating scars from burns (including on skin grafts) and in patients with mature keloids or hypertrophic scars. In a phase 2 Randomized Clinical Trial, our FS2 topical cream has shown significant superiority over the market leader in treatment of keloid scars, the most difficult type of scars to treat. Our plan is to partner this business this year with a leading company in the derma/skin care market, allowing a global outreach of FS2 topical cream to millions of people suffering from mild to severe skin disorders.